非小细胞肺癌（NSCLC）进展和转移与肿瘤微环境密切相关。肿瘤相关巨噬细胞（TAMs）是肿瘤微环境中一种重要的免疫调节细胞，其不仅抑制抗肿瘤免疫反应，还影响肿瘤干细胞（CSCs）的存活。申请人前期研究发现一种分泌IL-10的CD163+TAMs，其可作为诊断恶性胸水、判断患者预后、评估治疗疗效的指标，对促进恶性胸水进展发挥重要作用；同时，NSCLC组织CD163+TAMs较癌旁CD163+TAMs高表达IL-10。因此，推测CD163+TAMs通过分泌IL-10促进NSCLC-CSCs的形成，目前尚未明确。本研究拟采用qPCR、流式细胞术等技术分析CD163+TAMs对NSCLC-CSCs生物学特性的影响，利用IL-10受体（IL-10R）阻断性抗体及shRNA IL-10R进一步探讨CD163+TAMs促进CSCs的分子机制，阻断信号通路相关分子，为NSCLC患者治疗提供新的干预措施。

The progression and metastasis of non-small cell of lung cancer (NSCLC) are closely related to tumor microenvironment. Tumor-associated macrophages (TAMs) are the important regulatory immune cells in tumor microenvironment, which not only can inhibit the anti-tumor immune responses, but also affect the survival of cancer stem cells (CSCs). The preliminary study found that IL-10-secreted CD163+TAMs could serve as a biomarker for diagnosis and prognosis, and were associated with therapeutic effect of malignant pleural effusion, which suggest that CD163+TAMs play an important role in tumor progression. In addition, the expression level of IL-10 in NSCLC-derived CD163+TAMs was higher than that in peritumor-derived CD163+TAMs. Therefore, we hypothesis that CD163+TAMs could promote and regulate CSCs in NSCLC, which is still unclear. This study is to evaluate the impact of CD163+TAMs on the sphere forming, tumorgenicity, apoptosis and anti-cancer drug resistance of CSCs in vitro and in vivo by using real-time PCR and flow cytometry techniques, et al. In further, the use of anti-IL-10 receptor (IL-10R) antibody and shRNA IL-10R could give a way to the molecular mechanisms of the effect of CD163+ TAMs on CSCs of NSCLC. Finally, we will block the key moleculars of signaling pathway in order to find a novel measurement and method for the treatment of NSCLC.